Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | VNN1 | O95497 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18030367 | 0.82 | KDM4E (0.48) | KDM4EHDAC1HDAC6NAMPTALDH1A1 | |
| SCHEMBL23547606 | 0.76 | NPSR1 (0.44) | KDM4EALDH1A1NPC1LMNARAB9A | |
| SCHEMBL5423407 | 0.73 | KDM4E (0.60) | KDM4EHDAC1HDAC6ALDH1A1CYP19A1 | |
| SCHEMBL24754681 | 0.72 | PTGES (0.47) | — | |
| SCHEMBL2711073 | 0.70 | LMNA (0.41) | KDM4EALDH1A1LMNAKMT2A | |
| SCHEMBL12444444 | 0.70 | L3MBTL1 (0.58) | KDM4EHDAC1HDAC6ALDH1A1LMNA | |
| SCHEMBL12993708 | 0.69 | EPHX2 (0.54) | KDM4EHDAC1NAMPTALDH1A1LMNA | |
| SCHEMBL5431621 | 0.69 | KDM4E (0.67) | KDM4EHDAC1HDAC6ALDH1A1CYP19A1 | |
| SCHEMBL25044558 | 0.69 | L3MBTL1 (0.69) | KDM4EHDAC1HDAC6ALDH1A1LMNA | |
| SCHEMBL12326825 | 0.69 | NAMPT (0.59) | KDM4EHDAC1HDAC6NAMPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10300067-B2 | Tetrahydropyridopyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-05-28 | — | — | US | disclosed |
| US-20180161331-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180161331-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-06-14 | — | — | US | disclosed |
| US-9889136-B2 | Tetrahydropyridopyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-02-13 | — | — | US | disclosed |
| US-9889136-B2 | Tetrahydropyridopyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-02-13 | — | — | US | disclosed |
| US-9662333-B2 | Tetrahydropyridopyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-05-30 | — | — | US | disclosed |
| US-9662333-B2 | Tetrahydropyridopyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-05-30 | — | — | US | disclosed |
| EP-3150599-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2017-04-05 | — | — | EP | disclosed |
| US-20160310496-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-10-27 | — | — | US | disclosed |
| US-20160310496-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-10-27 | — | — | US | disclosed |
| US-20160244444-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-08-25 | — | — | US | disclosed |
| WO-2015182712-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINE COMPOUND OR SALT THEREOF | 大鵬薬品工業株式会社 | 2015-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161331-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINE COMPOUND OR SALT THEREOF | NR5A1, CYP17A1, AR | KDM4E 1995/4885HDAC1 69/4885HDAC6 240/4885 |
| US-10300067-B2 | Tetrahydropyridopyrimidine compound or salt thereof | NR5A1, CYP17A1, DPYD | KDM4E 2393/4885HDAC1 126/4885HDAC6 389/4885 |
| US-20160310496-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINE COMPOUND OR SALT THEREOF | NR5A1, CYP17A1, AR | KDM4E 1995/4885HDAC1 69/4885HDAC6 240/4885 |
| US-20160244444-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINE COMPOUND OR SALT THEREOF | AR, NR5A1, NR5A2 | KDM4E 1358/4885HDAC1 177/4885HDAC6 883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.